methyl N-[(2S)-1-[2-[(Z,2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-5-methylideneoct-6-enyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(2S)-1-[2-[(Z,2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-5-methylideneoct-6-enyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
• 化学式: C₃₇H₅₄N₆O₇
• 分子量: 694.9
• InChiKey: CBYWMKMBEXBRET-MRXQERQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  50
• 可旋转键数：
  19
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  171
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] PROCESS FOR PREPARING ATAZANAVIR SULPHATE<br/>[FR] PROCÉDÉ DE PRODUCTION DE SULFATE D'ATAZANAVIR
  申请人：CIPLA HOUSE

  公开号：WO2014125270A1

  公开（公告）日：2014-08-21

  The present invention relates to a process for the preparation of Compound (A): (Formula (A)) wherein the process comprises contacting atazanavir base (Compound (II)) with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compound (A), and to Compound (A) devoid of mesityl oxide impurity. Mesityl oxide has the following formula: (Formula (B)).